Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection
Background Some biologics for psoriasis, especially anti-tumor necrosis factor (TNF)-α therapies, may re-activate latent tuberculosis (TBC) infection with consequent morbidity and mortality. However, there is a low reported incidence of conversion to positive TBC status among patients with psoriasis...
Saved in:
| Main Authors: | Matteo Megna, Cataldo Patruno, Maria Rita Bongiorno, Alessio Gambardella, Claudio Guarneri, Caterina Foti, Serena Lembo, Francesco Loconsole, Gabriella Fabbrocini |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-07-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2022.2062280 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secukinumab: In psoriasis and beyond
by: Aditya K. Bubna, et al.
Published: (2025-01-01) -
Efficacy of Secukinumab in Management of Erythrodermic Psoriasis: A Study in Treatment-naïve Cases
by: Aradhana Rout, et al.
Published: (2025-07-01) -
Personalized Secukinumab Treatment in Patients with Plaque Psoriasis Using Model-Informed Precision Dosing
by: Karine Rodriguez-Fernandez, et al.
Published: (2024-12-01) -
Successful Treatment of Pediatric Generalized Pustular Psoriasis with Secukinumab
by: Yu K, et al.
Published: (2025-01-01) -
Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)